步長製藥(603858.SH):擬放棄優先受讓控股子公司股權
格隆匯11月13日丨步長製藥(603858.SH)公佈,公司控股子公司濟南步長晟源股東於海銘擬將其持有的1.00%股權轉讓給刁海龍,顧建明擬將其持有的1.00%股權轉讓給刁海龍,梁旭擬將其持有的1.00%股權轉讓給紀振霞,馬曉騰擬將其持有的1.00%股權轉讓給王春利,訾立賓擬將其持有的1.00%股權轉讓給邢傑,李龍廣擬將其持有的1.00%股權轉讓給徐偉,上述股權轉讓價格均擬按照1元/註冊資本。公司同意放棄上述股權轉讓的優先受讓權。本次轉讓完成後,公司持有濟南步長晟源90%股權比例不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.